Evoke Pharma Company Profile (NASDAQ:EVOK)

About Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma logoEvoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EVOK
  • CUSIP: N/A
  • Web: www.evokepharma.com
Capitalization:
  • Market Cap: $51.7 million
  • Outstanding Shares: 15,388,000
Average Prices:
  • 50 Day Moving Avg: $2.62
  • 200 Day Moving Avg: $2.69
  • 52 Week Range: $1.35 - $4.55
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.00
  • P/E Growth: -0.09
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.44 per share
  • Price / Book: 7.64
Profitability:
  • Return on Equity: -167.16%
  • Return on Assets: -80.56%
Debt:
  • Current Ratio: 7.03%
  • Quick Ratio: 7.03%
Misc:
  • Average Volume: 80,959 shs.
  • Beta: 1.11
  • Short Ratio: 17.91
 

Frequently Asked Questions for Evoke Pharma (NASDAQ:EVOK)

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.15. During the same quarter in the previous year, the business earned ($0.41) EPS. View Evoke Pharma's Earnings History.

When will Evoke Pharma make its next earnings announcement?

Evoke Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Evoke Pharma.

Where is Evoke Pharma's stock going? Where will Evoke Pharma's stock price be in 2017?

5 brokers have issued 12-month price targets for Evoke Pharma's stock. Their forecasts range from $6.00 to $9.00. On average, they anticipate Evoke Pharma's share price to reach $8.20 in the next year. View Analyst Ratings for Evoke Pharma.

What are analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:

  • 1. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (8/17/2017)
  • 2. FBR & Co analysts commented, "We think agreements reached with the FDA have provided Evoke Pharma with a clear regulatory path for advancing Gimoti as a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. The company has maintained its projection for filing a New Drug Application (NDA) for Gimoti’s FDA approval in late 2017 or early 2018. One particularly key positive development in 1Q17 was gaining an agreement that a Human Factors Validation Study would not be required prior to filing the NDA. We think investors have not fully recognized the value of this agreement, as conducting this study would have significantly delayed Gimoti’s approval. We look for near-term investor recognition of this and other de-risking factors to increase and result in positive stock outperformance vs. the NASDAQ Biotechnology Index in 2017 (up 30% versus up 11% YTD, respectively)." (5/18/2017)
  • 3. Ascendiant Capital Markets analysts commented, "Maintaining our BUY rating, but raising our 12-month price target to $6 from $5, which is based on an NPV analysis. Though we acknowledge that it is still at an early stage, we believe the large market potential presents a high reward for the risks." (3/16/2017)

Who are some of Evoke Pharma's key competitors?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the folowing people:

  • Cam L. Garner, Chairman and Co Founder
  • David A. Gonyer, CEO, Founder, Director
  • Matthew J. D'Onofrio, Executive Vice President, Chief Business Officer Treasurer, Secretary ,
  • Marilyn R. Carlson M.D., Chief Medical Officer
  • Todd Brady M.D., Director
  • Scott L. Glenn, Director
  • Ann D. Rhoads, Director
  • Ken Jon Widder M.D., Director

Who owns Evoke Pharma stock?

Evoke Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.40%), Sphera Funds Management LTD. (3.25%), State Treasurer State of Michigan (2.60%) and Precept Management LLC (0.62%). Company insiders that own Evoke Pharma stock include Kenneth J Widder and Parters Vii L P Domain. View Institutional Ownership Trends for Evoke Pharma.

Who bought Evoke Pharma stock? Who is buying Evoke Pharma stock?

Evoke Pharma's stock was purchased by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan and Vanguard Group Inc.. View Insider Buying and Selling for Evoke Pharma.

How do I buy Evoke Pharma stock?

Shares of Evoke Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of Evoke Pharma stock can currently be purchased for approximately $3.36.


MarketBeat Community Rating for Evoke Pharma (NASDAQ EVOK)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about Evoke Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Evoke Pharma (NASDAQ:EVOK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $8.20 (144.05% upside)

Analysts' Ratings History for Evoke Pharma (NASDAQ:EVOK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/18/2017HC WainwrightReiterated RatingBuy$9.00LowView Rating Details
5/18/2017FBR & CoReiterated RatingBuy$9.00LowView Rating Details
3/16/2017Ascendiant Capital MarketsBoost Price TargetIn-Line$5.00 -> $6.00HighView Rating Details
3/16/2017Rodman & RenshawReiterated RatingBuy -> Buy$6.00 -> $9.00HighView Rating Details
1/30/2017LaidlawUpgradeNeutral -> Buy$8.00N/AView Rating Details
8/16/2016Noble FinancialReiterated RatingHoldN/AView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
7/18/2016Feltl & Co.DowngradeStrong-Buy -> SellN/AView Rating Details
7/18/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Evoke Pharma (NASDAQ:EVOK)
Earnings by Quarter for Evoke Pharma (NASDAQ:EVOK)
Earnings History by Quarter for Evoke Pharma (NASDAQ EVOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.21)N/AView Earnings Details
8/14/2017Q2 2017($0.12)($0.27)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.16)($0.14)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.19)($0.12)ViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.29)ViewListenView Earnings Details
8/15/2016Q216($0.43)($0.41)ViewListenView Earnings Details
5/11/2016Q116($0.41)($0.45)ViewListenView Earnings Details
3/10/2016Q415($0.45)($0.37)ViewListenView Earnings Details
11/12/2015Q315($0.56)($0.42)ViewListenView Earnings Details
8/13/2015Q215($0.60)($0.52)ViewListenView Earnings Details
5/14/2015Q115($0.55)($0.58)ViewListenView Earnings Details
3/4/2015Q414($0.80)($0.48)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.78)($0.63)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.73)($0.59)ViewN/AView Earnings Details
5/13/2014Q114($0.38)($0.49)ViewN/AView Earnings Details
3/25/2014Q413($0.16)($0.27)ViewN/AView Earnings Details
11/13/2013Q3 13($0.10)($0.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Evoke Pharma (NASDAQ:EVOK)
2017 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.17)($0.17)($0.17)
Q2 20171($0.13)($0.13)($0.13)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Evoke Pharma (NASDAQ:EVOK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Evoke Pharma (NASDAQ:EVOK)
Insider Ownership Percentage: 20.00%
Institutional Ownership Percentage: 12.88%
Insider Trades by Quarter for Evoke Pharma (NASDAQ:EVOK)
Institutional Ownership by Quarter for Evoke Pharma (NASDAQ:EVOK)
Insider Trades by Quarter for Evoke Pharma (NASDAQ:EVOK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2017Kenneth J WidderDirectorBuy450,000$2.90$1,305,000.00View SEC Filing  
5/26/2016Parters Vii L P DomainMajor ShareholderSell344,120$4.70$1,617,364.00View SEC Filing  
4/27/2016Parters Vii L P DomainMajor ShareholderSell5,095$5.07$25,831.65View SEC Filing  
4/25/2016Parters Vii L P DomainMajor ShareholderSell1,492$5.20$7,758.40View SEC Filing  
4/20/2016Parters Vii L P DomainMajor ShareholderSell41,478$5.35$221,907.30View SEC Filing  
4/11/2016Parters Vii L P DomainMajor ShareholderSell4,348$5.22$22,696.56View SEC Filing  
4/8/2016Parters Vii L P DomainMajor ShareholderSell51,004$5.28$269,301.12View SEC Filing  
8/18/2015Parters Vii L P DomainMajor ShareholderSell11,836$7.02$83,088.72View SEC Filing  
4/16/2015Parters Vii L P DomainMajor ShareholderSell50,163$7.29$365,688.27View SEC Filing  
9/23/2014Todd C BradyDirectorBuy4,000$5.70$22,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Evoke Pharma (NASDAQ:EVOK)
Latest Headlines for Evoke Pharma (NASDAQ:EVOK)
Source:
DateHeadline
americanbankingnews.com logoEvoke Pharma, Inc. (EVOK) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - September 18 at 10:16 AM
americanbankingnews.com logoEvoke Pharma, Inc. (EVOK) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 16 at 10:56 PM
nasdaq.com logoEvoke Pharma Completes Dosing for Gimoti™ Comparative Exposure Pharmacokinetic Study - Nasdaq
www.nasdaq.com - September 12 at 7:18 PM
finance.yahoo.com logoEvoke Pharma Completes Dosing for Gimoti™ Comparative Exposure Pharmacokinetic Study
finance.yahoo.com - September 12 at 7:18 PM
globenewswire.com logoEvoke Pharma to Present at the 19th Annual Rodman & Renshaw Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 7 at 4:28 AM
americanbankingnews.com logoValuEngine Lowers Evoke Pharma, Inc. (EVOK) to Sell
www.americanbankingnews.com - September 3 at 1:26 PM
americanbankingnews.com logoEvoke Pharma, Inc. (EVOK) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - August 26 at 9:58 PM
americanbankingnews.com logoHead-To-Head Survey: Evoke Pharma (EVOK) vs. Innocoll Holdings PLC (INNL)
www.americanbankingnews.com - August 24 at 2:08 AM
americanbankingnews.com logoEvoke Pharma, Inc. (EVOK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 22 at 10:44 PM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - August 17 at 9:26 PM
americanbankingnews.com logoZacks: Analysts Anticipate Evoke Pharma, Inc. (EVOK) to Announce -$0.15 Earnings Per Share
www.americanbankingnews.com - August 17 at 8:18 AM
americanbankingnews.com logoEvoke Pharma, Inc. (EVOK) PT Set at $9.00 by HC Wainwright
www.americanbankingnews.com - August 15 at 6:40 PM
americanbankingnews.com logoEvoke Pharma, Inc. (EVOK) Posts Earnings Results, Misses Estimates By $0.15 EPS
www.americanbankingnews.com - August 15 at 12:46 PM
streetinsider.com logoEvoke Pharma (EVOK) Begins Comparative Exposure Pharmacokinetic Study for Gimoti
www.streetinsider.com - August 14 at 11:52 PM
reuters.com logoBRIEF-Evoke pharma inc initiates comparative exposure Pharmacokinetic Study for Gimoti
www.reuters.com - August 14 at 11:52 PM
finance.yahoo.com logoEvoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti™
finance.yahoo.com - August 14 at 11:52 PM
nasdaq.com logoEvoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti™ - Nasdaq
www.nasdaq.com - August 14 at 6:51 PM
globenewswire.com logoEvoke Pharma Reports Second Quarter 2017 Results and Highlights - GlobeNewswire (press release)
globenewswire.com - August 14 at 6:51 PM
finance.yahoo.com logoEvoke Pharma Reports Second Quarter 2017 Results and Highlights
finance.yahoo.com - August 14 at 6:51 PM
americanbankingnews.com logoEvoke Pharma, Inc. (NASDAQ:EVOK) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - August 11 at 8:32 PM
feeds.benzinga.com logoEvoke Pharma Schedules Conference Call and Webcast for Second Quarter 2017 Financial Results
feeds.benzinga.com - August 7 at 8:46 AM
americanbankingnews.com logo-$0.12 EPS Expected for Evoke Pharma, Inc. (NASDAQ:EVOK) This Quarter
www.americanbankingnews.com - July 30 at 7:26 AM
americanbankingnews.com logoEvoke Pharma, Inc. (EVOK) Downgraded by ValuEngine
www.americanbankingnews.com - July 28 at 11:02 PM
americanbankingnews.com logoEvoke Pharma, Inc. (EVOK) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 28 at 10:45 PM
americanbankingnews.com logoEvoke Pharma, Inc. (EVOK) Upgraded at ValuEngine
www.americanbankingnews.com - July 21 at 12:04 AM
prnewswire.com logoIRIDEX Announces Appointment Of Ann Rhoads To Its Board Of Directors - PR Newswire (press release)
www.prnewswire.com - July 18 at 5:07 PM
americanbankingnews.com logoEvoke Pharma, Inc. (NASDAQ:EVOK) Upgraded at ValuEngine
www.americanbankingnews.com - July 7 at 6:20 PM
americanbankingnews.com logoZacks: Analysts Expect Evoke Pharma, Inc. (EVOK) Will Announce Earnings of -$0.12 Per Share
www.americanbankingnews.com - July 5 at 10:16 PM
americanbankingnews.com logoEvoke Pharma, Inc. (NASDAQ:EVOK) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 3 at 10:40 PM
americanbankingnews.com logo Brokerages Anticipate Evoke Pharma Inc (EVOK) Will Announce Earnings of -$0.12 Per Share
www.americanbankingnews.com - June 10 at 12:28 AM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - June 9 at 3:50 PM
nasdaq.com logoGeneric Drugs Stocks on Investors' Radar -- Catalyst Pharma, Lannett, Evoke Pharma, and Galectin Therapeutics
www.nasdaq.com - June 7 at 11:23 AM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 6 at 10:46 PM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - June 4 at 6:14 PM
nasdaq.com logoEvoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti - Nasdaq
www.nasdaq.com - June 1 at 5:48 PM
streetinsider.com logoEvoke Pharma (EVOK) Enters Agreement with Rho to Submit Gimoti NDA
www.streetinsider.com - May 31 at 5:03 PM
reuters.com logoBRIEF-Evoke Pharma enters agreement with Rho to submit NDA for Gimoti
www.reuters.com - May 31 at 5:03 PM
finance.yahoo.com logoEvoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti
finance.yahoo.com - May 31 at 5:03 PM
globenewswire.com logoEvoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti - GlobeNewswire (press release)
globenewswire.com - May 31 at 9:27 AM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Evoke Pharma Inc Issued By FBR & Co (EVOK)
www.americanbankingnews.com - May 19 at 7:24 AM
americanbankingnews.com logoFBR & Co Reiterates "Buy" Rating for Evoke Pharma Inc (EVOK)
www.americanbankingnews.com - May 18 at 4:40 PM
globenewswire.com logoEvoke Pharma Reports First Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - May 17 at 10:50 AM
reuters.com logoBRIEF-Evoke Pharma Q1 loss per share $0.37 - Reuters
www.reuters.com - May 16 at 10:04 PM
nasdaq.com logoEvoke Pharma Reports First Quarter 2017 Results - Nasdaq
www.nasdaq.com - May 16 at 10:04 PM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Issues Quarterly Earnings Results, Misses Estimates By $0.21 EPS
www.americanbankingnews.com - May 15 at 9:20 PM
finance.yahoo.com logoInvestor Network: Evoke Pharma, Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 4:46 PM
finance.yahoo.com logoEvoke Pharma Reports First Quarter 2017 Results
finance.yahoo.com - May 15 at 4:46 PM
americanbankingnews.com logo-$0.14 Earnings Per Share Expected for Evoke Pharma Inc (EVOK) This Quarter
www.americanbankingnews.com - May 15 at 2:22 PM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 12 at 10:58 PM
globenewswire.com logoEvoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week ... - GlobeNewswire (press release)
globenewswire.com - May 11 at 5:44 PM

Social

Chart

Evoke Pharma (EVOK) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff